Redeye comments on Embracers Q3 2022/23 report. Net sales came in 6% higher than our estimates, whil...
Taaleri reported Q4 EBIT of EUR 7.1m, coming 24% below Refinitiv consensus at EUR 9.
Redeye comments on Medivir's fourth quarter report.
Q4 net sales came in 1% above our estimate, but clean EBIT was 7% below our expectation.
Redeye comments on Sprint Bioscience’s Q4 2022 report, and we judge that the company is closing in o...
Redeye strengthens its positive view of Formpipe following the solid Q4 report showing a record-high...
Q4 de-risks 2023 estimates Strategy update: 2025 targets reiterated '23e adj.
Redeye comments on CSECs partially guaranteed rights issue of a total of SEK 9.
2022e sales cut by 4% Q4 global smartphone shipments -17% y-o-y Announced commercial activities in Q...
The production ramp-up in Pampalo developed as expected during H2 2022, although profitability was i...
Agtira closed its books for 2022 reaching record high sales of 25.
Valutamedvind och starkt kassaflöde Operativt CF blev 26 mkr, vilket var det starkaste kvartalet sed...
Rapportkommentar OncoZenge presenterade under gårdagen sin rapport för det fjärde kvartalet.
ESL Shipping segment was a positive surprise compared to our estimates in Q4, one reason being coal ...
Redeye sees no big drama in the Q4 report. Coating Services was a bit sluggish as some customers sti...
Redeye comments on Alelion's Q4 report, which was softer than expected due to component shortages st...
Redeye is encouraged by the positive results at the Waupaca Foundry, where both the employees are sa...
Adj. EBIT SEK -9.7m vs. ABGSCe -7.1m NWT sales at SEK 5.
Safeture's revenue was in line with Redeye's estimate, but the ARR and OPEX came in below.
Etteplan reports its Q4 results on February 17th. Sights are already set on the outlook for 2023, wi...
